<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231438</url>
  </required_header>
  <id_info>
    <org_study_id>SUS2010GOLA01</org_study_id>
    <secondary_id>2010-020415-36</secondary_id>
    <nct_id>NCT01231438</nct_id>
  </id_info>
  <brief_title>Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.</brief_title>
  <official_title>An Open, Randomized, Crossover Phase 2 Pilot Study of Treatment of Stage 3B Renal Failure With Active Vitamin D or a Phosphate Binder to Evaluate the Effect on the FGF23 and PTH Levels.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rikshospitalet University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with reduced renal function normally develop hyperparathyroidism, which in turn is
      associated with increased cardiovascular risk and de-calcification. Hyperparathyroidism may
      be enhanced by an increased level of FGF23 which is often seen in the early stage of renal
      failure. This pilot study will investigate the FGF23-lowering effect of early initiation of
      treatment with a phosphate binder versus active vitamin D in an open crossover design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FGF23 serum level</measure>
    <time_frame>Change over 2 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium serum level</measure>
    <time_frame>Change over 2 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphate serum level</measure>
    <time_frame>Change over 2 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTX-1 serum level</measure>
    <time_frame>Change over 2 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PINP serum level</measure>
    <time_frame>Change over 2 weeks of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTH serum level</measure>
    <time_frame>Change over 2 weeks of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Renvela</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etalpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vit D Treatment for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renvela</intervention_name>
    <description>800mg t.i.d. over 2 weeks</description>
    <arm_group_label>Renvela</arm_group_label>
    <other_name>Sevelamercarbonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etalpha</intervention_name>
    <description>0.25ug o.d. for 2 weeks</description>
    <arm_group_label>Etalpha</arm_group_label>
    <other_name>Alfakalsidol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal failure stage 3B

          -  25(OH)vitamin D level above 50 nmol/l

          -  Age over 18 years

          -  Written consent

        Exclusion Criteria:

          -  Major surgery during the previous 6 months

          -  Myocardial infarct during the previous 6 months

          -  Unstable heart failure

          -  Ongoing treatment for any malignancy

          -  History of frequent infections

          -  Pregnancy

          -  Ongoing treatment with steroids, lithium or biphosphonates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lasse Göransson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Stavanger HF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo Universitetssykehus Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0372</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>NO-4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Bleskestad IH, Bergrem H, Hartmann A, Godang K, Gøransson LG. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial. BMC Nephrol. 2012 Jun 28;13:49. doi: 10.1186/1471-2369-13-49.</citation>
    <PMID>22742720</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2010</study_first_submitted>
  <study_first_submitted_qc>October 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <last_update_submitted>November 8, 2012</last_update_submitted>
  <last_update_submitted_qc>November 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal failure stage 3B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

